Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B

Archiv der Pharmazie

Volumn 340, Issue 8, 2007, Pages 389-395

  Warnecke, André ^a   Fichtner, Iduna ^b   Saß, Gretel ^c   Kratz, Felix ^a  

^a TUMOR BIOLOGY CENTER   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c MEDAC GMBH   (Germany)

Author keywords

Cathepsin B; Human serum albumin; Macromolecular prodrug; Methotrexate; Plasmin

Indexed keywords

CATHEPSIN B; MALEIMIDE DERIVATIVE; METHOTREXATE; PLASMIN; PRODRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; DRUG INHIBITION; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTON NUCLEAR MAGNETIC RESONANCE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CATHEPSIN B; FEMALE; HUMANS; METHOTREXATE; MICE; MICE, INBRED DBA; PLASMIN; PRODRUGS; PROTEIN BINDING; SERUM ALBUMIN;

EID: 34548067350     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.200700025     Document Type: Article

References (32)

1. R. Haag, F. Kratz, Angew. Chem. Int. Ed. 2006, 45, 1198-1215.
2. Y. Matsumura, H. Maeda, Cancer Res. 1986, 46, 6387-6392.
3. A. Goel, S. S. Chauhan, Indian J. Exp. Biol. 1997, 35, 553-564.
4. C. Ruppert, S. Ehrenforth, I. Scharrer, E. Halberstadt, Cancer Detect. Prev. 1997, 21, 452-459.
5. J. Decock, R. Paridaens, T. Cufer, Curr. Opin. Oncol. 2005, 17, 545-550.
6. C. Jedeszko, B. F. Sloane, Biol. Chem. 2004, 385, 1017-1027.
7. B. Fingleton, Front. Biosci. 2006, 11, 479-491.
8. K. Dano, N. Behrendt, G. Hoyer-Hansen, M. Johnsen, et al., Thromb. Hoemost. 2005, 93, 676-681.
9. A. W. Partin, G. E. Hanks, E. A. Klein, J. W. Moul, et al., Oncology 2002, 16, 1218-1224.
10. D. E. Chung, F. Kratz, Bioorg. Med. Chem. Lett. 2006, 16, 5157-5163.
11. F. Kratz, A. Mansour, J. Soltau, A. Warnecke, et al., Arch. Pharm. 2005, 338, 462-472.
12. B. Schmid, D.-E. Chung, A. Warnecke, I. Fichtner, F. Kratz, Bioconjugate Chem. 2007, 18, 702-716.
13. A. M. Mansour, J. Drevs, N. Esser, F. M. Hamada, et al., Cancer Res. 2003, 63, 4062-4066.
14. F. Kratz, J. Drevs, G. Bing, C. Stockmar, et al., Bioorg. Med. Chem. Lett. 2001, 11, 2001-2006.
15. F. M. de Groot, A. C. de Bart, J. H. Verheijen, H. W. Scheeren, J. Med. Chem. 1999, 42, 5277-5283.
16. G. M. Dubowchik, R. A. Firestone, Bioorg. Med. Chem. Lett. 1998, 8, 3341-3346.
17. A. Rosowsky, R. Forsch, J. Uren, M. Wick, J. Med. Chem. 1981, 24, 1450-1455.
18. F. Kratz, A. Warnecke, K. Scheuermann, C. Stockmar, et al., J. Med. Chem. 2002, 45, 5523-5533.
19. A. M. Mansour, J. Drevs, N. Esser, F. M. Hamada, et al., Cancer Res. 2003, 63, 4062-4066.
20. A. Warnecke, I. Fichtner, D. Garmann, U. Jaehde, F. Kratz, Bioconjugate Chem. 2004, 15, 1349-1359.
21. A. Warnecke, F. Kratz, Bioconjugate Chem. 2003, 14, 377-387.
22. F. Kratz, R. Muller-Driver, I. Hofmann, J. Drevs, C. Unger, J. Med. Chem. 2000, 43, 1253-1256.
23. B. Werle, W. Ebert, W. Klein, E. Spiess, Anticancer Res. 1994, 14, 1169-1176.
24. K. Riebeseel, E. Biedermann, R. Löser, N. Breiter, et al., Bioconjugate Chem. 2002, 13, 773-785.
25. G. Hartung, G. Stehle, H. Sinn, A. Wunder, et al., Clin. Cancer Res. 1999, 5, 753-759.
26. A. N. Vis, A. van der Gaast, B. W. van Rhijn, T. K. Catsburg, et al., Cancer Chemother. Pharmacol. 2002, 49, 342-345.
27. C. Boiling, T. Graefe, C. Lubbing, F. Jankevicius, et al., Invest. New Drugs 2006, 24, 521-527.
28. G. Stehle, H. Sinn, A. Wunder, H. H. Schrenk, et al., Anti-cancer Drugs 1997, 8, 677-685.
29. G. Stehle, A. Wunder, H. Sinn, H. H. Schrenk, et al., Anti-cancer Drugs 1997, 8, 835-844.
30. K. Wosikowski, E. Biedermann, B. Rattel, N. Breiter, et al., Clin. Cancer Res. 2003, 9, 1917-1926.
31. A. Rosowsky, R. A. Forsch, J. H. Freisheim, J. Galivan, M. Wick, J. Med. Chem. 1984, 27, 888-893.
32. J. J. Fitzpatrick, M. C. Garnett, Anti-Cancer Drug Design 1995, 10, 1-9.